AAA Biotech Expands Recombinant Proteins Portfolio to Advance Life Sciences Research

AAA Biotech has announced the expansion of its recombinant proteins (rProteins) portfolio, reinforcing its position as a global leader in providing high-quality research reagents for the life sciences sector. This development is set to significantly impact biomedical research by offering scientists and researchers access to a broader range of tools for their experiments.

The company's recombinant proteins are produced through specific, controlled genetic engineering methods, ensuring high purity and activity. With purities usually exceeding 95%, these proteins are available in various formats, including multiple tags for easy purification and detection. This level of quality control is crucial for researchers aiming to achieve precise and reliable results in their studies.

AAA Biotech's rProteins can be expressed in a variety of systems, such as prokaryotic (E. coli) and eukaryotic (HEK293, CHO, yeast, insect) cells, catering to the diverse needs of folding, post-translational modification, and functionality. This flexibility is essential for a wide range of applications, including protein-protein and protein-DNA interactions, functional biological assays, and drug discovery.

Moreover, the company offers custom variants, allowing researchers to tailor expressions and tags to their specific experimental requirements. Each product undergoes rigorous quality control, including SDS-PAGE, endotoxin testing, and activity assays, ensuring researchers receive only the highest quality reagents.

For more information on AAA Biotech's comprehensive range of research reagents, visit their official website at https://www.aaabiotech.com/.